MAC: Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer

Sponsor
Oregon State University (Other)
Overall Status
Completed
CT.gov ID
NCT04559854
Collaborator
OHSU Knight Cancer Institute (Other)
28
1
1
15.2
1.8

Study Details

Study Description

Brief Summary

The objectives of this study are to: 1) adapt a mindfulness-based therapy program designed to help women manage their sexual and body image concerns after cancer (Mindful After Cancer, MAC) to a videoconference format and 2) assess the feasibility, acceptability, and preliminary effects of the program among breast and gynecologic cancer survivors.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindful After Cancer
N/A

Detailed Description

The specific aims are: 1) Assess the feasibility of the MAC program when delivered via videoconference and 2) Assess preliminary effects of the the program.

Study Design

Study Type:
Interventional
Actual Enrollment :
28 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Mindful After Cancer Study: Fostering Positive Body Image, Sexual Health, and Well-being
Actual Study Start Date :
Jul 1, 2019
Actual Primary Completion Date :
Oct 1, 2020
Actual Study Completion Date :
Oct 5, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindful After Cancer

Participants will be asked to attend 8 weekly sessions via videoconference, and to complete home activities and mindfulness practice between sessions.

Behavioral: Mindful After Cancer
The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.

Outcome Measures

Primary Outcome Measures

  1. Feasibility/ Enrollment [Baseline]

    Number of participants enrolled, Proportion of participants enrolled of those eligible

  2. Feasibility/ Retention in Study [1 month post-intervention]

    Number and proportion of participants completing all assessments

  3. Feasibility/ Retention in the Program [1 month post-intervention]

    Mean number of sessions attended, Proportion of participants attending at least 6 of 8 sessions

  4. Acceptability [1 month post-intervention]

    Endorsement of 10 items characterizing acceptability (e.g., the program met my expectations). Range 10-100. Higher score indicates better acceptability.

Secondary Outcome Measures

  1. Change from baseline self-efficacy at 1 month [Baseline and 1 month post-intervention]

    Self-efficacy for Managing Chronic Disease Scale (adapted). 6 items. Range 6-60. Higher score indicates better self-efficacy for managing sexual health after cancer.

  2. Change from baseline body image at 1 month [Baseline and 1 month post-intervention]

    Body Image Scale. 10 items. Range 0-30. Higher score indicates poorer body image.

  3. Change from baseline body appreciation at 1 month [Baseline and 1 month post-intervention]

    Body Appreciation Scale. 13 items. Range 13-65. Higher score indicates more positive body appreciation.

  4. Change from baseline anxiety at 1 month [Baseline and 1 month post-intervention]

    PROMIS Emotional Distress Anxiety Short Form 6a. 6 items. Range 6-30. Raw scores are translated to a T score following PROMIS guidelines. Higher score indicates greater anxiety symptoms.

  5. Change from baseline depression at 1 month [Baseline and 1 month post-intervention]

    Center for Epidemiologic Studies Depression Scale (CES-D). 20 items. Range 0-60. Higher score indicates greater depressive symptoms

  6. Change in facets of baseline mindfulness at 1 month [Baseline and 1 month post-intervention]

    Five-Facet Mindfulness Questionnaire (FFMQ-15). 15 items with 5 sub-scales: Observe, Describe; Act with Awareness; Non-Judgement, Non-Reactivity. Sub-scale score range 3-15. Higher score indicates greater mindfulness.

  7. Change from baseline self-compassion at 1 month [Baseline and 1 month post-intervention]

    Self-Compassion Scale short form. 12 items. Range 12-60. Higher score indicates greater self-compassion.

  8. Change from baseline relationship quality at 1 month [Baseline and 1 month post-intervention]

    Dyadic Adjustment Scale short form (DAS-7). Range 0-36. Higher score indicates more positive relationship quality

  9. Change from baseline interest in sexual activity at 1 month [Baseline and 1 month post-intervention]

    PROMIS SexFS 2.0. 2 items. Range 2-10. Raw scores are translated to a T score following PROMIS guidelines. Higher score indicates more interest in sexual activity.

  10. Change from satisfaction with sex life at 1 month [Baseline and 1 month post-intervention]

    New Sexual Satisfaction Scale- Short Form (NSSS-S). 12 items. Range 12-60. Higher score indicates more sexual satisfaction.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 89 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of breast or gynecologic cancer at least one year prior to enrollment

  • English speaking

  • Have access to a computer, smart phone, or tablet with internet access

  • Ability to spend 15-30 minutes per day on program activities

Exclusion Criteria:
  • Stage 0 (carcinoma in situ)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Oregon State University Corvallis Oregon United States 97331

Sponsors and Collaborators

  • Oregon State University
  • OHSU Knight Cancer Institute

Investigators

  • Principal Investigator: Jessica R Gorman, PhD, MPH, Oregon State University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Oregon State University
ClinicalTrials.gov Identifier:
NCT04559854
Other Study ID Numbers:
  • 20181004
First Posted:
Sep 23, 2020
Last Update Posted:
Dec 3, 2020
Last Verified:
Dec 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Dec 3, 2020